Published in final edited form as:

J Biotechnol. 2017 October 20; 260: 62–66. doi:10.1016/j.jbiotec.2017.09.005.

Induced Prodrug Activation by Conditional Protein Degradation

Andrew S. Gaynor¹ and Wilfred Chen¹

¹Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, USA

Abstract

Enzyme prodrug therapies hold potential as a targeted treatment option for cancer patients. However, off-target effects can be detrimental to patient health and represent a safety concern. This concern can be alleviated by including a failsafe mechanism that can abort the therapy in healthy cells. This feature can be included in enzyme prodrug therapies by use of conditional degradation tags, which degrade the protein unless stabilized. We call this process Degradation-Directed Enzyme Prodrug Therapy (DDEPT). Herein, we use traceless shielding (TShld), a mechanism that degrades a protein of interest unless it is rescued by the addition of rapamycin, to test this concept. We demonstrated that TShld rapidly yielded only native protein products within 1 h after rapamycin addition. The rapid protection phenotype of TShld was further adapted to rescue yeast cytosine deaminase, a prodrug converting enzyme. As expected, cell viability was adversely affected only in the presence of both 5-fluorocytosine (5-FC) and rapamycin. We believe that the DDEPT system can be easily combined with other targeting strategies to further increase the safety of prodrug therapies.

Keywords

prodrug; antitumor agents; protein therapy; traceless shielding; protein engineering

1. Introduction

Enzyme prodrug therapies are an attractive alternative to conventional chemotherapies due to their potential to elicit a localized, targeted toxic effect at the tumor site (Altaner, 2008; Andrady et al., 2011). One example is use of yeast cytosine deaminase (yCD), which converts a non-toxic prodrug, 5-fluorocytosine (5-FC), to the clinically prevalent cytotoxic drug, 5-fluorouracil (5-FU), for the treatment of glioblastoma (Polak et al., 1976; Zhang et al., 2015). Proposed methods for introducing prodrug converting enzymes (PCEs) require the targeted delivery of the enzyme to the cancer, as any off-target activity would kill the benign cell upon addition of the prodrug (Biela et al., 2003; Fong et al., 2011; Tian et al., 2013; Wang et al., 2015). While many methods have tested successful for targeting tumors *in vitro*, none are completely free of risk and safety concerns. Activation based on targeting extracellular cancer markers may lack the required specificity as these markers are presented at certain levels on healthy cells as well (Bildstein et al., 2011). More importantly, we lack

any means of regulating the intracellular protein levels after delivery as there is no innate mechanism for clearing the PCE in an event of promiscuous delivery.

One way to address this issue is to impose an additional layer of cell-specificity by controlling intracellular enzyme levels in a process we coin “Degradation-Directed Enzyme Prodrug Therapy (DDEPT): Healthy cells would quickly degrade the PCE and remain unscathed while cancerous cells, through a targeted activation mechanism, would preserve the PCE towards a therapeutic outcome. DDEPT is most conveniently executed by simply grafting a conditional degradation domain (DD) to the PCE (Bonger et al., 2011; Caussinus et al., 2012; Chung et al., 2015; Iwamoto et al., 2010; Pratt et al., 2007), which under normal circumstances is recognized and swiftly eliminated by the proteasome, but the DD can be stabilized by the introduction of a chemical cue. This approach is simple but leaves behind a DD-PCE fusion protein, which may affect its endogenous biological activity. An improved technology termed Traceless Shielding (TShld) was recently reported to generate native proteins, in which a chemical cue is used to both shield the target proteins from degradation and trigger their release from the DD (Lau et al., 2010). Briefly, TShld consists of two separate constructs that function together to rescue the protein of interest. On the first construct, the protein payload is flanked by a conditional DD, FKBP, which is stabilized by the small molecule rapamycin (Banaszynski et al., 2006; Banaszynski et al., 2008), and the C-terminus of ubiquitin (UbC, residues 35–76). In the absence of rapamycin, FKBP destabilizes the complex containing the payload, resulting in its degradation. In addition to stabilizing FKBP, rapamycin also induces complementation between FKBP and the second construct consisting of FRB, a domain from the mTOR protein, and the N-terminus of ubiquitin (UbN, residues 1–37), resulting in reconstitution of the split ubiquitin and separation of the protein of interest from the rest of the complex via ubiquitin hydrolases (Fig. 1) (Johnsson and Varshavsky, 1994; Stagljar et al., 1998). Intrigued by the dual capability of TShld to provide conditional PCE rescue in a native conformation, we demonstrated the principle of DDEPT using TShld for the conditional rescue of yCD and controlled prodrug activation as an initial step towards a novel therapeutic direction.

2. Materials and methods

2.1. Plasmid construction

All constructs were prepared using standard molecular cloning techniques. pEntry TShld-GFP was a gift from Matthew Pratt (Addgene plasmid #53211). TShld GFP was cloned into pcDNA3.1 (Invitrogen), and mCherry was cloned onto the N-terminus. For cell viability experiments, GFP TShld yCD was cloned as follows: yCD was substituted for GFP and GFP was substituted for mCherry as the global protein expression control.

2.2. Cell Culture

HeLa cells were maintained in T150 tissue culture flasks (Thermo Fisher) in Minimum Essential Media (MEM, Cellgro) supplemented with 10% fetal bovine serum (FBS, Corning) and 1% penicillin/streptomycin (HyClone) at 37°C and 5% CO₂.

2.3. Transfection

Plasmid DNA was prepared using ZymoPURE™ Plasmid Midiprep Kit (Zymo Research) according to the manufacture's protocol. HeLa cells were seeded at roughly 175,000 cells/well in 12-well plates (Corning) supplemented MEM as described above. One day after seeding, transfection was achieved with Lipofectamine® 3000 (Invitrogen) using 1 µg plasmid DNA per well and following the manufacture's protocol. Transfection occurred for a minimum of 12 hours.

2.4. Endpoint Cell Culture Experiments

Transfected cells were treated with the appropriate amount of rapamycin (LC Laboratories, >99% purity) and 5-FC (Sigma-Aldrich, >99% purity) to achieve the desired final concentrations in a total volume of 1 mL for 24 hours. Cells were washed twice in 1 mL pre-warmed imaging buffer (140 mM NaCl, 2.5 mM KCl, 1.8 mM CaCl₂, 1.0 mM MgCl₂, 20 mM HEPES, pH 7.4). Cells were then incubated in 0.5 mL of pre-warmed imaging buffer throughout microscopy. For viability studies, 1 drop of NucRed® Dead 647 ReadyProbes® Reagent (Invitrogen) was added and allowed to incubate at room temperature for 2 minutes prior to imaging.

2.5. Fluorescent Microscopy and Image Analysis

All images were captured using an Observer Z.1 Inverted Microscope (Zeiss) with GFP, mCherry, or Cy5 filter cube sets (Chroma). For image analysis, five images were captured in each well. Image analysis was conducted using the "Measure" analysis in ImageJ with threshold set 10–255. Error bars represent the 95% confidence interval.

2.6. TShld Time Course Experiments

HeLa cells were seeded in individual 35 mm tissue culture-treated culture dishes (Corning) and transfected as described above. Transfected cells were treated with 500 nM rapamycin in a total of 1 mL of media. Each hour, one plate was removed from the incubator, washed twice in 1 mL pre-warmed cell imaging buffer, and imaged in 0.5 mL of imaging buffer.

2.7. Western Blotting

Following imaging, cells were incubated in ice-cold lysis buffer (50 mM Tris, 150 mM NaCl, 1% Triton X-100, pH 8.0) on ice for 20 minutes with protease inhibitor cocktail (Calbiochem). Cells were then removed from the plate with a cell scraper (Genemate), and the lysate was clarified in a pre-cooled centrifuge at 12,000 rpm for 10 minutes at 4°C. Total protein concentrations were normalized through a Bradford assay (Bio-Rad) with a BSA standard. 15 µg of lysate was mixed with a 5x loading buffer and separated by 10% SDS-PAGE before being transferred to a nitrocellulose membrane (Bio-Rad).

Western blots were blocked in TBST (20 mM Tris, 500 mM NaCl, 0.05% Tween-20, pH 8.0) containing 5% non-fat milk overnight at room temperature with gentle shaking. Membranes were washed twice in TBST and incubated for 3 hours in anti-GFP (1:5000 dilution, Covance) or anti-mCherry (1:2000 dilution, Novus) in TBS. The blots were then washed twice in TBST and incubated with horseradish peroxidase (HRP)-conjugated

secondary antibody (GenScript) for 2 hours in TBST. The blots were washed three times in TBST and developed using ECL reagents (GE) according to the manufactures protocol. Band intensities were quantified using ImageJ gel analysis tools.

3. Results

3.1. Appending a global protein expression marker to TShld

Previous reports on the TShld system have clearly indicated the release of target proteins 48 h after rapamycin addition. However, it was unclear whether the initial protection was mainly due to DD stabilization or DD release. Since the two protein complexes are expressed under one promoter and are translated into two individual constructs using the T2A viral “self-cleaving” peptide (Holst et al., 2006; Szymczak et al., 2004), we first fused mCherry to the N-terminus of FRB-UbN to allow direct monitoring of total protein synthesis. Similar to other reports, GFP was fused to the C-terminus of FKBP-UbC to enable easy tracking of protein rescue in a rapamycin dosage-dependent manner. HeLa cells were transfected with the mCherry-TShld-GFP construct. Cells were then cultured in a specified concentration of rapamycin ranging from 0–1000 nM in media for 24 h, and the abundance of mCherry and GFP was probed by both Western blotting and microscopy. As expected, the levels of mCherry fluorescence were unaffected by the rapamycin concentration in the media (Fig. S1). However, only a low level of GFP fluorescence was detected in the absence of rapamycin, which increased significantly in a dosage-responsive manner until 500 nM of rapamycin, at which point the maximum signal was observed (Fig. 2A, Fig. S2). Overall, a 11.2-fold difference in normalized GFP fluorescence was observed between 0 and 1000 nM of rapamycin (Fig. 2B).

3.2. Protein release from DD occurs rapidly

Western blotting was used to further probe the mechanism of GFP rescue. Only a small quantity of cleaved GFP product was detectable before rapamycin addition, indicative of efficient degradation and a low level of background cleavage. However, the DD tag cleavage via ubiquitin hydrolase was extremely rapid, and only cleaved GFP was detected even 1 h after rapamycin addition (Fig. 2C). The level of cleaved GFP increased slightly with time after the addition of rapamycin, while the level of mCherry-FRB-UbN remained constant (Fig. 2C and 2D). It is clear that the initial DD (FKBP) stabilization by rapamycin is also very rapid, a condition necessary for the subsequent quick release of GFP from the reconstituted ubiquitin by ubiquitin hydrolase.

3.4. DDEPT requires both protein rescue and prodrug to reduce cell viability

Having demonstrated the rapid rescue and release of native GFP by rapamycin addition, we next sought to execute DDEPT through the dynamic control of yCD levels using the TShld system in order to regulate the degree of 5-FC conversion to 5-FU and the corresponding cell viability. We first replaced mCherry with GFP as the expression marker because of the higher fluorescence intensity and yCD as the TShld payload. After transfection, the levels of GFP expression and cell viability were compared in the presence or absence of rapamycin ranging from 0–1000 nM and/or 300 μ M 5-FC. To distinguish healthy cells from dead cells, we employed the NucRed® Dead 647 ReadyProbes® Reagent, which stains the genomic

DNA of non-viable cells whose membrane integrity is compromised. No discernible difference in the GFP level was observed regardless of 5-FC and/or rapamycin addition, indicating their addition has no effect on protein expression. The addition of rapamycin by itself had no impact on cell viability across the spectrum of rapamycin added, and these levels were statistically similar to the group that received only 5-FC (Fig. 3A and 3C). These results again support the need of both 5-FC and active yCD for prodrug activation. In contrast, cell viability decreased in a rapamycin dosage-responsive manner in the presence of 5-FC as reflected by the higher number of purple fluorescent cells (Fig. 3B and 3C). Since the GFP level remained fairly constant independent of rapamycin and 5-FC addition, this observation implies that the increase in cytotoxicity is not a result of increased protein synthesis but a direct effect of yCD rescue by rapamycin addition.

4. Discussion

In summary, we reported here a new DDEPT approach to provide conditional prodrug activation based on controlled protein degradation. This approach capitalized on the well-known feature of the TShld system to both rescue the prodrug activating enzyme, yCD, from degradation as well as its release from the DD upon rapamycin addition. By tagging the two TShld components with fluorescence proteins, we were able to discern that protein rescue was mainly the result of rapid DD release as only native proteins were detected even 1 h after rapamycin addition. The small background levels in the absence of rapamycin can be attributed to the low level of split ubiquitin complementation as previously reported (Lin and Pratt, 2014). For prodrug activation, this low level of background yCD rescue did not impact cell viability as even the introduction of 5-FC was not sufficient to cause cytotoxicity. Only in the presence of both 5-FC and rapamycin did we observe significant cell death. This approach allows the advantages of both targeted prodrug therapy in addition to a mechanism for clearing PCEs from healthy cells. This work represents an important first step in utilizing the DDEPT concept towards targeted prodrug activation. Looking forward, DDEPT would further benefit from autonomous switching such that the presence or absence of a specific cancer marker would determine the fate of the PCE thus rendering it independent of a small molecular trigger. For example, yCD has been engineered to accumulate only in cells that overexpress hypoxia-inducible factor 1 α , common in many cancers (Wright et al., 2011). Furthermore, delivery platforms have been developed that specifically target unique markers such as human growth factor receptor 2 on the surface of breast cancer cells (Man and Kullberg, 2016), allowing DDEPT to be used as a gene therapy combined with the additional failsafe of the PCE degradation.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgement

This work is partially funded by NSF (CBET1510817). The authors would like to thank M.R. Pratt for the generous gift of TShld-GFP.

Abbreviations:

yCD	yeast cytosine deaminase
5-FC	5-fluorocytosine
5-FU	5-fluorouracil
PCE	prodrug converting enzyme, prodrug converting enzyme
DDEPT	degradation-directed enzyme prodrug therapy
DD	degradation domain
TShld	traceless shielding
FKBP	FK506 binding protein
FRB	FKBP12-Rapamycin Binding Domain
mTOR	mechanistic target of rapamycin

5. References

- Altaner C, 2008 Prodrug cancer gene therapy. *Cancer Letters* 270, 191–201. [PubMed: 18502571]
- Andrady C, Sharma SK, Chester KA, 2011 Antibody–enzyme fusion proteins for cancer therapy. *Immunotherapy* 3, 193–211. [PubMed: 21322759]
- Banaszynski LA, Chen LC, Maynard-Smith LA, Ooi AG, Wandless TJ, 2006 A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. *Cell* 126, 995–1004. [PubMed: 16959577]
- Banaszynski LA, Sellmyer MA, Contag CH, Wandless TJ, Thorne SH, 2008 Chemical control of protein stability and function in living mice. *Nat Med* 14, 1123–1127. [PubMed: 18836461]
- Biela BH, Khawli LA, Hu P, Epstein AL, 2003 Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT). *Cancer biotherapy & radiopharmaceuticals* 18, 339–353. [PubMed: 12954121]
- Bildstein L, Dubernet C, Couvreur P, 2011 Prodrug-based intracellular delivery of anticancer agents. *Adv Drug Deliv Rev* 63, 3–23. [PubMed: 21237228]
- Bonger KM, Chen L. c., Liu CW, Wandless TJ, 2011 Small-molecule displacement of a cryptic degron causes conditional protein degradation. *Nat Chem Biol* 7, 531–537. [PubMed: 21725303]
- Caussinus E, Kanca O, Affolter M, 2012 Fluorescent fusion protein knockout mediated by anti-GFP nanobody. *Nat Struct Mol Biol* 19, 117–121.
- Chung HK, Jacobs CL, Huo Y, Yang J, Krumm SA, Plemper RK, Tsien RY, Lin MZ, 2015 Tunable and reversible drug control of protein production via a self-excising degron. *Nat Chem Biol* 11, 713–720. [PubMed: 26214256]
- Fong V, Osterbur M, Capella C, Kim YE, Hine C, Gorbunova V, Seluanov A, Dewhurst S, 2011 Adenoviral vector driven by a minimal Rad51 promoter is selective for p53-deficient tumor cells. *PLoS One* 6, e28714.
- Holst J, Vignali KM, Burton AR, Vignali DA, 2006 Rapid analysis of T-cell selection in vivo using T cell-receptor retrogenic mice. *Nat Methods* 3, 191–197. [PubMed: 16489336]
- Iwamoto M, Bjorklund T, Lundberg C, Kirik D, Wandless TJ, 2010 A general chemical method to regulate protein stability in the mammalian central nervous system. *Chem Biol* 17, 981–988. [PubMed: 20851347]
- Johnson N, Varshavsky A, 1994 Split ubiquitin as a sensor of protein interactions in vivo. *Proc Natl Acad Sci U S A* 91, 10340–10344. [PubMed: 7937952]

- Lau HD, Yaegashi J, Zaro BW, Pratt MR, 2010 Precise Control of Protein Concentration in Living Cells. *Angewandte Chemie International Edition* 49, 8458–8461. [PubMed: 20878685]
- Lin YH, Pratt MR, 2014 A Dual Small-Molecule Rheostat for Precise Control of Protein Concentration in Mammalian Cells. *Chembiochem* 15, 805–809. [PubMed: 24615791]
- Mann K, Kullberg M, 2016 Trastuzumab-Targed Gene Delivery to Her2-Overexpression Breast Cancer Cells. *Cancer Gene Ther* 23, 221–228. [PubMed: 27199219]
- Polak A, Eschenhof E, Fernex M, Scholer HJ, 1976 Metabolic studies with 5-fluorocytosine-6-14C in mouse, rat, rabbit, dog and man. *Chemotherapy* 22, 137–153. [PubMed: 773604]
- Pratt MR, Schwartz EC, Muir TW, 2007 Small-molecule-mediated rescue of protein function by an inducible proteolytic shunt. *Proceedings of the National Academy of Sciences* 104, 11209–11214.
- Stagljär I, Korostensky C, Johnsson N, te Heesen S, 1998 A genetic system based on split-ubiquitin for the analysis of interactions between membrane proteins in vivo. *Proc Natl Acad Sci U S A* 95, 5187–5192. [PubMed: 9560251]
- Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin EF, Vignali DA, 2004 Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. *Nat Biotechnol* 22, 589–594. [PubMed: 15064769]
- Tian D, Sun Y, Yang Y, Lei M, Ding N, Han R, 2013 Human telomerase reverse-transcriptase promoter-controlled and herpes simplex virus thymidine kinase-armed adenoviruses for renal cell carcinoma treatment. *OncoTargets and therapy* 6, 419–426. [PubMed: 23723709]
- Wang H, Zhou XL, Long W, Liu JJ, Fan FY, 2015 A Fusion Protein of RGD4C and beta-Lactamase Has a Favorable Targeting Effect in Its Use in Antibody Directed Enzyme Prodrug Therapy. *International journal of molecular sciences* 16, 9625–9634. [PubMed: 25927583]
- Wright CM, Wright RC, Eshleman JR, Ostermeier M, 2011 A Protein Therapeutic Modality Founded on Molecular Regulation. *Proc Natl Acad Sci U S A* 108, 16206–16211. [PubMed: 21930952]
- Zhang J, Kale V, Chen M, 2015 Gene-Directed Enzyme Prodrug Therapy. *The AAPS Journal* 17, 102–110. [PubMed: 25338741]

Fig. 1.

Schematic representation of mCherry TShld GFP protein product. The transcribed DNA includes the entirety of the protein under one promotor. A T2A site between the proteins forces the synthesis of two separate proteins due to ribosome skipping at the Gly-Pro junction of the T2A peptide (left). In the absence of rapamycin, FKBP is destabilized, targeting itself and its fusion partners, including GFP, towards degradation. The first part of the construct, including mCherry, does not contain a degradation tag and is not subject to induced degradation (top right). In the presence of rapamycin (black triangle containing the letter "R"), FKBP is stabilized and FRB is recruited to FKBP, promoting a close proximity between UbC and UbN. GFP is cleaved from the construct, rescuing it from possible degradation. Both mCherry and GFP can now be detected (bottom right).

Fig. 2. mCherry serves as a marker for protein synthesis in the TShld system and can be used to probe the initial mechanism of protection. (a) Microscopy of HeLa cells demonstrates the dosage response of GFP levels to rapamycin while mCherry levels are maintained as constant. Images were obtained 24 hours following the addition of rapamycin. (b) Quantification of fluorescent images showing statistically significant increases in GFP level relative to the mCherry transfection marker between all doses of rapamycin through 500 nM ($n = 5$, $** p < 0.01$, $*** p < 0.001$). (c) Western blots probing for mCherry and GFP reveals constant mCherry-FRB-UbN expression with GFP protein levels quickly increasing over time. The response is rapid, leaving no uncleaved GFP detected, indicating that initial protection results from DD release. Quantification of the western blot band intensities shows the GFP time profile immediately following rescue initiation. The absolute intensity was different for the two proteins as mCherry-FRB-UbN was probed with anti-mCherry primary antibody and GFP was probed with anti-GFP antibody. (d) Fluorescent microscopy corroborates the findings of the western blot analysis.

Fig. 3.

Cell death is only induced by the presence of both rapamycin and 5-FC. All images were obtained 24 hours after the addition of rapamycin and/or 5-FC. (a) Images of HeLa cells demonstrating that rapamycin alone is insufficient to induce cell death. GFP indicates high levels of protein synthesis, yet cell viability is maintained at all doses of rapamycin. (b) Images of HeLa cells demonstrating that the combination of rapamycin-induced yCD rescue and the prodrug 5-FC results in dosage-responsive cell killing. (c) Quantification of the fluorescent images with nuclear dye (cell death) normalized to GFP (transfection). All

concentrations of rapamycin 50 nM are statistically different between each 0 μ M 5-FC group and its corresponding 300 μ M 5-FC group. Cell killing is dosage responsive to rapamycin concentration (n = 5, * p < 0.05, ** p < 0.01, *** p < 0.001, NS p > 0.05).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript